$0.11
(Market cap
$314 Mln
Recently Viewed
Clear AllMarket cap
$314 Mln
Revenue (TTM)
$6 Mln
P/E Ratio
5.4
P/B Ratio
2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
1.9
Debt to Equity
0.2
Book Value
$2.4
EPS
$1.1
Face value
--
Shares outstanding
57,049,023
CFO
$-331.09 Mln
EBITDA
$-372.52 Mln
Net Profit
$-486.80 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Abeona Therapeutics (ABEO)
| 4.4 | 11.1 | 4.8 | 13.4 | 25.4 | -31.8 | -22.4 |
|
BSE Sensex
| -7.3 | 4.0 | -6.1 | 1.9 | 9.1 | 10.0 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Abeona Therapeutics (ABEO)
| -5.4 | 11.1 | 62.7 | -63.8 | -78.3 | -52.0 | -54.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Abeona Therapeutics (ABEO)
|
5.5 | 313.8 | 5.8 | 71.2 | -1,536.9 | 70 | 5.4 | 2.0 |
| 69.5 | 9,733.6 | 1,091.0 | 202.3 | 31.6 | 31.3 | 43.4 | 17.1 | |
| 244.5 | 15,009.4 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 66.7 | 8,216.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.9 | 11,658.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.3 | |
| 90.4 | 11,852.6 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 532.0 | 12,204.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.3 | |
| 520.6 | 14,867.3 | 2,530.2 | 451.1 | 21.3 | 70.2 | 34 | 32.4 | |
| 107.6 | 8,460.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.8 | |
| 342.5 | 9,538.9 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients... with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio. Read more
President, CEO & Director
Dr. Vishwas Seshadri M.B.A., Ph.D.
President, CEO & Director
Dr. Vishwas Seshadri M.B.A., Ph.D.
Headquarters
Cleveland, OH
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Abeona Therapeutics Inc (ABEO) is $5.49 (NASDAQ) as of 17-Apr-2026 16:29 EDT. Abeona Therapeutics Inc (ABEO) has given a return of 25.39% in the last 3 years.
The P/E ratio of Abeona Therapeutics Inc (ABEO) is 5.45 times as on 17-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
4.90
|
2.19
|
|
2024
|
-3.59
|
5.19
|
|
2023
|
-2.36
|
8.64
|
|
2022
|
-0.55
|
0.82
|
|
2021
|
-0.02
|
0.03
|
The 52-week high and low of Abeona Therapeutics Inc (ABEO) are Rs 7.54 and Rs 4.00 as of 19-Apr-2026.
Abeona Therapeutics Inc (ABEO) has a market capitalisation of $ 314 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Abeona Therapeutics Inc (ABEO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.